Skip to main content
BioCentury on BioBusiness
Feature Story

Metamorphoses of Ovid

How Ovid will work with patients to repurpose drugs for rare brain disease

By Susan Schaeffer, Editor

Neurology company Ovid Therapeutics Inc. is already tapping into the expertise of its new CEO, veteran dealmaker Jeremy Levin. The biotech is in-licensing molecules that have reached Phase III testing but are not approved in the U.S., and where there is a mechanism-based rationale for development in rare and Orphan diseases of the brain.

Hardly the first company to attempt to repurpose failed drugs, Ovid may have an ace up its sleeve in the form of extremely close ties to patients and their families, who will have a role in shaping development of the company's drug candidates.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial